FDA批准治疗体液潴留的药械组合,MannKind股价攀升

路透中文
Jul 24
BUZZ-FDA批准治疗体液潴留的药械组合,MannKind股价攀升

7月24日 - ** 制药公司曼恩康德(MannKind, MNKD.O)的股价在盘前交易中上涨6.4%,至4.13美元

** 该公司表示,美国食品药品监督管理局(FDA)已批准其一次性注射剂Furoscix ReadyFlow,用于治疗心力衰竭或慢性肾病成人患者的体液潴留或水肿

** 该自动注射器将呋塞米药物注入皮下,其药物暴露量相当于静脉注射,可在1小时内或更短时间内缓解症状

** MannKind表示,此次批准得到了 (link) 积极临床数据的支持,数据显示该药物在体内的代谢过程完全符合预期,能够安全有效地发挥作用

** 截至上一交易日收盘,该股年内累计跌幅达31.4%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10